setlona 0,120 mg/0,015 mg na 24 ur, vaginalni dostavni sistem
mylan ireland limited - etinilestradiol; etonogestrel - vaginalni dostavni sistem - etinilestradiol 3,474 mg / 1 dostavni sistem etonogestrel11 mg / 1 dostavni sistem; etonogestrel 11 mg / 1 dostavni sistem - vaginalni obroček s progestogenom in estrogenom
setlona 0,120 mg/0,015 mg na 24 ur, vaginalni dostavni sistem
mylan ireland limited - etinilestradiol; etonogestrel - vaginalni dostavni sistem - etinilestradiol 3,474 mg / 1 dostavni sistem etonogestrel11 mg / 1 dostavni sistem; etonogestrel 11 mg / 1 dostavni sistem - vaginalni obroček s progestogenom in estrogenom
nuvaring 0,120 mg/0,015 mg na 24 ur vaginalni dostavni sistem
merck sharp & dohme, d.o.o. - etinilestradiol; etonogestrel - vaginalni dostavni sistem - etinilestradiol 2,7 mg / 1 sistem etonogestrel11,7 mg / 1 sistem; etonogestrel 11,7 mg / 1 sistem - vaginalni obroček s progestogenom in estrogenom
nuvaring 0,120 mg/0,015 mg na 24 ur vaginalni dostavni sistem
merck sharp & dohme, d.o.o. - etinilestradiol; etonogestrel - vaginalni dostavni sistem - etinilestradiol 2,7 mg / 1 sistem etonogestrel11,7 mg / 1 sistem; etonogestrel 11,7 mg / 1 sistem - vaginalni obroček s progestogenom in estrogenom
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastična sredstva - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
drovelis
gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - spolni hormoni in zdravila genitalni sistem, - oral contraceptive.
lydisilka
estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - spolni hormoni in zdravila genitalni sistem, - peroralna kontracepcija. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.
etonogestrel/etinilestradiol mithra pharmaceuticals 0,120 mg/0,015 mg na 24 ur vaginalni dostavni sistem
etinilestradiol; etinilestradiol; etonogestrel - vaginalni dostavni sistem - etinilestradiol 2,7 mg / 1 sistem etinilestradiol2,7 mg / 1 sistem etonogestrel11,7 mg / 1 sistem; etinilestradiol 2,7 mg / 1 sistem etonogestrel11,7 mg / 1 sistem; etonogestrel 11,7 mg / 1 sistem - vaginalni obroček s progestogenom in estrogenom
gestoden/etinilestradiol gedeon richter 60 mikrogramov/15 mikrogramov
etinilestradiol; gestoden - filmsko obložena tableta - etinilestradiol 15 µg / 1 tableta gestoden60 µg / 1 tableta; gestoden 60 µg / 1 tableta - gestoden in etinilestradiol
gestoden/etinilestradiol gedeon richter 60 mikrogramov/15 mikrogramov
etinilestradiol; gestoden - filmsko obložena tableta - etinilestradiol 15 µg / 1 tableta gestoden60 µg / 1 tableta; gestoden 60 µg / 1 tableta - gestoden in etinilestradiol